TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

FRIENDSWOOD, Texas–(BUSINESS WIRE)—- $CSTL #AI–Study shows TissueCypher outperformed pathology review in predicting progression to high-grade dysplasia or esophageal cancer in Barrett’s patients.
Click here to view original post